Sarcoidal alopecia is a subtype of plaque-forming cutaneous sarcoidosis that may resemble discoid lupus erythematosus (DLE). Because the clinical appearance of the two lesions is similar, the correct diagnosis may be missed. The systemic involvement and progressive nature of sarcoidosis, make it important to differentiate sarcoidal alopecia from DLE, so that proper treatment can be initiated and potential longterm sequelae avoided. We present the case of a 57-year-old Taiwanese woman with sarcoidal alopecia of the scalp that mimicked DLE.
Introduction
Sarcoidosis is an idiopathic systemic granulomatous disease, in which noncaseating granulomatous inflammation can occur in any organ. The skin is affected in about 25% of cases, and the majority of cases occur in black women. 1 The scalp is rarely involved, and the inflammation may lead to cicatricial alopecia as a result of the destruction of hair follicles by the granulomatous formation. 1 Clinically, sarcoidosis may present as papules, nodules, or plaques, and in some cases may resemble discoid lupus erythematosus (DLE) or necrobiosis lipoidica.
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Case report
A 57-year-old Taiwanese female had been very healthy most of her life. However, over the past 4e5 years, she had developed painful ulcerative wounds with alopecia on her frontoparietal scalp ( Figure 1 ). She had not been treated for the wounds or alopecia prior to visiting our hospital. On examination, we saw several beanto coin-sized depressed ulcers surrounded by a violaceous to erythematous hue, and telangiectasia on the right frontoparietal scalp. No other skin lesions were noted. DLE was suspected, and an incisional biopsy was performed. The pathology report showed noncaseating granulomatous inflammation involving the superficial and deep dermis ( Figure 2 ). The granulomas were composed of epithelioid cells and occasional giant cells, rich in asteroid bodies. Results of direct immunofluorescence tests for immunoglobulin A (IgA), IgG, IgM, complement component 3 (C3), fibrinogen, and complement C1q were all negative. Periodic acid Schiff, Fite, and acid-fast stains did not reveal any pathogens, and the Venereal Disease Research Laboratory (VDRL) test was negative. Therefore, the diagnosis of sarcoidal alopecia was confirmed.
The immunologic profiles, including antinuclear antibody, antiextracted nuclear antigen (ENA) antibody, C3, and C4 were all within normal ranges. However, plain chest films and computed tomography (CT) scans revealed pulmonary sarcoidosis with lymphadenopathy ( Figure 3 ). Lung function tests showed normal spirometric values and diffusing capacity. Ophthalmologic examination ruled out any ocular involvement. The results of other blood tests, such as complete blood cell counts, and measurement of serum aspartate aminotransferase, alanine aminotransferase, creatinine, blood urea nitrogen, sodium, potassium and calcium levels, were all within normal limits.
Because the patient refused treatment with systemic corticosteroids, she was treated with oral hydroxychloroquine, 400 mg daily, and intralesional injections of triamcinolone, 10 mg once a month. She received a total of nine intralesional triamcinolone injections from October 2009 to December 2011; these injections were given on a monthly basis, except during the 18 months from April 2010 to September 2011.
Because the patient had significant overall improvement and regrowth of hair, we discontinued local corticosteroid treatment in January 2012. The dosage of oral hydroxychloroquine was also tapered to 200 mg daily (beginning February 2012) and the disease 
Discussion
Sarcoidal alopecia is a rare manifestation of cutaneous sarcoidosis that predominantly affects black women. 1 It is a form of secondary cicatricial alopecia and can have variable morphologies. Most commonly, cutaneous sarcoidosis on the frontoparietal facial region may extend into the scalp, which may lead to hair loss. Such lesions are the type of sarcoidal alopecia that most mimics DLE clinically.
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On the scalp, sarcoidosis can manifest as atrophic, erythematous, scaly, or ulcerative areas of alopecia. 1 The typical appearance of DLE is of well-circumscribed, erythematous, scaly, atrophic plaques, that may occasionally also be ulcerative. 2 In both situations, follicular plugging can be observed on dermoscopy. 5 The differential diagnosis of sarcoidal alopecia and DLE can be made by histopathologic examination. Sarcoidal alopecia shows classic naked granulomas in the dermis. 1e4 In contrast, DLE is characterized by follicular plugging, epidermal atrophy, vacuolar degeneration of basal keratinocytes, and basement membrane thickening, as well as superficial and deep perivascular and periadnexal lymphocytic infiltrates.
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Patients with sarcoidal alopecia almost always have other cutaneous lesions, and the vast majority of cases will also demonstrate systemic involvement.
1 About 30% of patients with the initial form of cutaneous sarcoidosis will develop its systemic form within months to several years of diagnosis. 6 Therefore, it is recommended that any patient with cutaneous sarcoidosis be screened for systemic lesions, even if there are no clinical complaints of systemic involvement at initial visits. Several diagnostic studies can be performed during the workup of sarcoidosis, including chest films, chest CT scans, and pulmonary function tests. A review of the English literature revealed 47 reported cases of scalp sarcoidosis, including ours. 1,3,7e16 In these studies, patients were predominantly female (35/40). Where race was mentioned, Figure 1 Cicatricial alopecia with several bean-to coin-sized depressed ulcers. A surrounding violaceous to erythematous hue can be seen on the patient's right frontoparietal scalp. 23 of 36 patients were black and three patients were Chinese. Many of the patients (32 of 37) exhibited extracutaneous involvement, and the lung was the most frequently involved site. Other extracutaneous manifestations included lymphadenopathies (18 of 37 patients), musculoskeletal involvement (4 of 37 patients), hepatosplenomegaly (3 of 37 patients), and ocular involvement (2 of 37 patients).
Our review of cases documented diverse morphologies of scalp sarcoidosis, including papules, nodules, indurative plaques, scales, and ulcers. Most of these cases showed scarring alopecia, but some cases of non-scarring alopecia have also been reported. 1, 3 Sarcoidal alopecia may resemble DLE, lichen planopilaris (follicular lichen planus), pseudopelade of Brocq (alopecia cicatrisata), necrobiosis lipoidica, morphea or alopecia neoplastica. DLE is the most confusing form. A comparison of the features of sarcoidal alopecia and DLE is presented in Table 1 . Given the limited clinical data available, it is difficult to draw definite conclusions about responses to therapy, prognosis, and outcome for patients with sarcoidal alopecia. Some authors have reported having poor responses with multiple treatments, including intralesional and/or systemic corticosteroids, antimalarials, and azathioprine. The overall response to treatment appears poor, but more information and analysis of more cases are needed before accurate conclusions can be made.
The standard treatment for sarcoidosis is systemic corticosteroids. Topical corticosteroids are often ineffective in treating sarcoidal alopecia, because of their inadequate depth of penetration into the skin. Combination antimalarial therapy (hydroxychloroquine plus quinacrine or chloroquine plus quinacrine) can be valuable after single-agent antimalarial therapy has failed. 1 The rationale of using antimalarial therapy in cutaneous sarcoidosis is based on the ability of these agents to inhibit antigen processing and presentation by antigen presenting cells to CD4þ T cells. 17 Antimalarials may raise the pH within lysosomes, thus preventing assembly of major histocompatibility complex (MHC)epeptide complexes and transport to the cell's surface. Without antigen processing and presentation via MHCepeptide complexes, no T cells are activated to promote granuloma formation. 17 Antimalarial agents have a relatively long history of use in the treatment of sarcoidosis, and are regarded as standard therapy. Typically, they are used in combination with corticosteroids, or singly for patients in whom corticosteroids are undesirable or unnecessary for long-term treatment. Based on reported clinical experience, the primary benefit of antimalarials appears to be their ability to suppress the formation of cutaneous lesions. 18 In our case, due to the disfigurement from the scalp lesions and our patient's hesitance to be treated with systemic corticosteroids, we administered hydroxychloroquine and intralesional corticosteroids simultaneously. DLE and several other diseases that resemble cutaneous sarcoidosis are relatively benign. Because of its characteristic clinical appearance and infrequent association with systemic lupus erythematosus, therapy for DLE is often administered without histologic confirmation of lesions. 2 This precludes identification of its close clinical simulation, cutaneous sarcoidosis. In our practice, we stress the importance of performing a skin biopsy to confirm the diagnosis of DLE on the scalp and to exclude sarcoidal alopecia. Because of the systemic and progressive nature of sarcoidosis, it is critical that this distinction is made and that the patient be treated accordingly. 2 Even though our patient did not receive any systemic corticosteroid treatment because of her personal preference, the identification of sarcoidosis did help; disease monitoring would enable us to provide appropriate treatment, should the disease progress. Cicatricial alopecia presents a diagnostic challenge for clinicians, particularly because the lesions of cutaneous sarcoidosis of the scalp may resemble DLE. Pathological examination is required to make the correct diagnosis, which then leads to effective treatment. 
